Thomas A. Raffin

Dr. Thomas Raffin is co-founder and general partner in Telegraph Hill Partners, a life sciences and healthcare private equity firm. Dr. Raffin has spent 27 years on the faculty at Stanford University School of Medicine, where he remains the Colleen and Robert Haas Professor Emeritus of Medicine and Biomedical Ethics, former Chief of Pulmonary and Critical Care Medicine and co-founder and director emeritus of the Stanford University Center for Biomedical Ethics. Over the past decade, Dr. Raffin has worked extensively in the healthcare and medical device sectors and is co-founder of Rigel Pharmaceuticals. Dr. Raffin has been a director of AngioScore, Confirma, Freedom Innovations, LDR, NewLink Genetics and PneumRx, an observer on the Boards of Vidacare and Estech, and has been an advisor to numerous other companies. As an investigator at Stanford and the Brigham he has more than 200 publications. Dr. Raffin received a BA from Stanford University and an MD from Stanford University School of Medicine and medical residency at Harvard.